LLYPartnership•prnewswire•
Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity
Sentiment:Positive (65)
Summary
Collaboration focused on undisclosed GPCR targets Company to receive an upfront and near-term payments, including an equity investment, as well as additional development and commercial milestones, and tiered royalties BOSTON, Aug. 14, 2025 /PRNewswire/ -- Superluminal Medicines, a drug...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 14, 2025 by prnewswire